Journal
ALZHEIMERS & DEMENTIA
Volume 14, Issue 8, Pages 989-997Publisher
WILEY
DOI: 10.1016/j.jalz.2018.02.013
Keywords
Plasma tau; Plasma phosphorylated tau; Amyloid PET; Tau PET; Alzheimer's disease; Predicting brain amyloid
Categories
Funding
- National Institutes of Health/National Institute on Aging [U01 AG006786, R01 AG011378, R01 AG041851, P50 AG16574, R01 AG049704]
- GHR Foundation
- Rochester Epidemiology Project [R01 AG034676]
Ask authors/readers for more resources
Introduction: We examined and compared plasma phospho-tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid beta (A beta) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain AO. Methods: Participants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent A beta PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181. Results: Plasma total tau and pTau181 levels were higher in AD dementia patients than those in cognitively unimpaired. Plasma pTau181 was more strongly associated with both A beta and tau PET. Plasma pTau181 was a more sensitive and specific predictor of elevated brain A beta than total tau and was as good as, or better than, the combination of age and apolipoprotein E (APOE). Discussion: Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain A beta. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available